August 25th 2025
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
August 19th 2025
The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications
August 15th 2025
Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised
August 14th 2025
Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond
August 13th 2025
New financing will support the company's lead retinitis pigmentosa programme, among other projects
Post-hoc analyses of YOSEMITE/RHINE trials compare faricimab results to aflibercept
The YOSEMITE/RHINE studies measured changes in the BCVA and CST from baseline to years 1 and 2
Inaugural Ramin Tadayoni Award will be granted at 2024 EURETINA Congress
The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research
RetinAI Discovery from Ikerian receives Class IIa MDR registration in EU
The diagnostic and monitoring tools use artificial intelligence-based models
Beacon Therapeutics treats first patient in global registration trial for X-linked retinitis pigmentosa therapeutic
XLRP often leads to blindness by middle age with no treatment options currently available
Combining imaging modalities could enable earlier identification of diabetic retinopathy
The mapping method revealed prominent microscopic abnormalities consistent with DR
Why imaging is key to managing geographic atrophy
Paying attention to high-resolution OCT is more important than ever
NIDEK announces CE mark for IOL injector, launch of new OCT device
The NP-1/NP-1C preloaded IOL injector has already been made available in parts of Asia
Risk factors for retinal detachment in Marfan syndrome after paediatric lens removal
Investigators put forth a list of considerations for surgeons ahead of lens removalin paediatric patients
Topical drop treatment for full-thickness macular hole closure
Investigators reported findings from the first study of successful macular hole closure using topical therapy
Espansione Group receives CE Mark approval for eye-light® photobiomodulation device
The flagship, light-based technology has received approval for applications in the anterior and posterior segments
European Commission grants Marketing Authorisation for bevacizumab gamma
The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)
Post hoc analysis shows how pegcetacoplan may impact RPE atrophy
Analysis of the OAKS and DERBY trials showed reduced growth rates of SD-OCT biomarkers for geographic atrophy
Professor Noemi Lois awarded Edinburgh King James IV Professorship by The Royal College of Surgeons
Professor Lois accepted the award at the Royal College of Ophthalmologists Annual Congress
United States FDA approves two aflibercept 2 mg biosimilars
The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen
Predicting visual acuity with a machine learning system
For decoding biomarkers, a multistage system is just the beginning
The evolving role of vitreosurgical simulators in surgical training
Need for accuracy results in optimisation of training for novice surgeons
Outlook Therapeutics submits UK Marketing Authorisation Application for wet AMD treatment
The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March
ARVO 2024: Mutation agnostic optogenetic programme demonstrates possible treatment for patients with severe retinal degeneration
Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting
Going beyond the clinical setting in ophthalmic mentorship
Three leaders in glaucoma research, retina care and refractive surgery share their expertise
ARVO 2024: President-elect SriniVas Sadda, MD, shares his strategies for engaging vision experts worldwide
Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology
ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease
The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease
ARVO 2024: Assessing melanocortin receptors and inflammation in the ocular space
Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting
ARVO 2024: Functional microperimetric correlates of OCT structural features in AMD
At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD
ARVO 2024: New data on diabetic retinopathy lesions from the DRCR Retina Network
Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression
ARVO 2024: Baruch Kuppermann, MD, PhD, discusses durability of a pan-VEGF tyrosine kinase inhibitor
Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation
ARVO 2024: An adaptable deep learning model for geographic atrophy segmentation
Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting
ARVO 2024: Insights on dry AMD and geographic atrophy from the GALE study of pegcetacoplan
At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan
ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes
Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy
ARVO 2024: Murine model of multiple sclerosis demonstrates correlation between visual markers and motor-sensory deficits
Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model
May is Inherited Retinal Disease Genetic Testing Awareness Month, Prevent Blindness expands on previous weeklong campaign
During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education